Trial Profile
Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALPS
- 01 Jun 2018 Status changed from active, no longer recruiting to completed, according to the results published in the Cancer Chemotherapy and Pharmacology
- 20 May 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2011 New trial record